Climb Bio: How a modified antibody could change the market for kidney diseases
Reading Time: 3 minutes
Climb Bio (CLYM) focuses on its lead product CLYM116 aimed at the addressable market for IgA Nephropathy (IgAN). Recent analyst comments from H.C. Wainwright and Oppenheimer raise the price potential to up to 30 USD, representing an upside potential of over 90%. A differentiated mechanism of action allows for a 12-week dosing interval, which could support peak sales of up to 1 billion USD. Focus on immune-mediated diseases and targeted B-cell therapies The biotechnology company Climb Bio (CLYM) strategically aligns its corporate strategy towards...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
